Join the conversation

Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Loading...Loading...Loading...Loading...

Trending Tickers

SLS logo
Top trending tickerSLS
$8.38
6.55%
#1
SELLASs Phase 3 REGAL trial of its AML candidate GPS has reached the event threshold for final survival analysis, with topline results expected in November. Traders are focused on the approaching binary readout and volatile after-hours trading, with some speculating about a data leak or short covering while others warn the moves may be noise and stress that the outcome remains uncertain.
CAPR logo
CAPR
$8.22
13.75%
#2
Capricor is in focus ahead of the FDAs Nov. 22 decision on Deramiocel for Duchenne muscular dystrophy, with traders debating whether the amended applications upper-limb data can overcome concerns about the statistical analysis and the companys earlier regulatory setbacks. The recent Summit Therapeutics rejection has added caution for some as CAPR shares slide, while others argue the drugs and FDA reviews are not comparable.
INFQ logo
INFQ
$7.97
6.01%
#3
Infleqtions Q3 report is the main focus: traders are weighing a revenue miss and wider losses against reaffirmed full-year guidance, a strong cash position, and progress toward quantum-computing milestones. The reaction is split between concerns about near-term execution and the stocks sharp decline alongside the broader quantum and tech selloff, and bullish views that liquidity and long-term commercialization prospects support the thesis.
NOK logo
NOK
$7.46
7.56%
#4
Nokia shares are under pressure amid traders focus on reports that Nvidia reduced its stake, alongside a broader retreat in AI-linked stocks; some blame the move for the selloff, while others see the pullback as an opportunity based on Nokias AI-networking and telecom prospects. Bearish posts warn of further losses, but some investors argue the companys infrastructure business supports a longer-term case.
OMER logo
OMER
$15.15
13.38%
#5
Omeros latest quarterly report has put YARTEMLEAs growing U.S. launch and transplant-center adoption in focus, alongside improved operating cash flow. Traders are split: some view the commercial momentum as strong, while others cite the selloff after the report, the GAAP loss and concerns that results or forward growth did not exceed expectations enough.
JPM logo
JPM
$337.25
2.58%
#6
A Chase software issue delaying some transactions is driving discussion; JPMorgan has attributed the delays to a bug and said there is no evidence of a cyberattack. Traders are split between accepting that explanation and speculating about a broader hack, while shares are also under pressure alongside the market.
UAL logo
UAL
$109.21
0.09%
#7
A widespread United system outage disrupting departing flights is driving attention, coming shortly after an FAA communications failure triggered a nationwide ground stop. Traders are debating whether the recurring disruptions are a technical glitch or something more serious, while some view the operational setbacks as a reason for caution and others are buying the dip.
TSN logo
TSN
$63.76
8.40%
#8
Tyson shares are rallying after quarterly results beat expectations, with traders focusing on the prospect of sharply reduced beef losses and a possible return to profitability in that segment. The reaction is tempered by weaker fiscal 2027 sales guidance and concerns about chicken profitability, leaving debate over whether the beef improvement outweighs broader headwinds.
SNDK logo
SNDK
$818.90
7.47%
#9
A sharp selloff in AI and semiconductor stocks has dragged SanDisk lower, as traders worry that slower AI data-center spending could weaken memory and storage demand; Nvidia leadership turmoil and broader tech-market weakness are adding to the pressure. The community is split between bears warning that the AI trade and cyclical memory demand are rolling over and bulls pointing to SanDisks earnings and valuation, with the upcoming stock split also drawing attention.
HELP logo
HELP
$7.72
12.97%
#10
Helus Pharmas Phase 3 APPROACH trial met its primary endpoint, with strong, sustained efficacy for HLP003 in major depression, but the shares fell as investors focused on three treatment-related serious adverse events, including a suicide attempt. Traders disagree on how concerning the safety disclosure is, while some also cite future financing and dilution risks despite the positive data.

About Stocktwits

With over 10 million users, Stocktwits helps you tap into the real-time sentiment and trending insights across stocks, ETFs, and crypto.